M. Docteur MARTIN BADARD
✨ Profil synthétique
IA · 04/05/2026Le Dr. Martin Badard est un rhumatologue exerçant à Paris, avec des publications sur PubMed portant sur les traitements anti-TNF et la lombalgie. Ses travaux de recherche suggèrent une expertise dans le domaine des maladies rhumatismales traitées par thérapies biologiques. Il est actif dans le domaine de la rhumatologie, avec un intérêt particulier pour les affections du rachis.
Expertises présumées
- Lombalgie
- Thérapies anti-TNF
- Rhumatologie du rachis
- Maladies inflammatoires du rachis
- Spondylarthropathies
- Thérapies biologiques en rhumatologie
- Douleurs chroniques du dos
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Bibliographie
A national media mass campaign improves beliefs and behaviours about low back pain in the general population and in general practitioners
2023ArticleJoint Bone Spine
Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials.
2021ArticleArthritis Research & Therapy
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Localisation des cabinets
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieux de consultation
CABINET DU DR MARTIN BADARD
55 RUE CORTAMBERT, 75016 Paris
Libéral© OpenStreetMapCABINET DU DR MARTIN BADARD
28 BOULEVARD SAINT MARCEL, 75005 Paris
Libéral© OpenStreetMapGHU APHP SUN SITE PITIE SALPETRIERE
47-83 — 47 Boulevard DE L HOPITAL, 75651 Paris 13e Arrondissement
☎ 0142160000Hospitalier
Tarifs & secteur de conventionnement
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials
Arthritis research & therapy · 2021
Lire l'abstract Crossref ↓
Abstract Background Anterior uveitis (AU) is the most frequent extra-articular feature of axial spondyloarthritis (axSpA). We aimed to assess and compare the incidence of AU in axSpA patients treated with anti-TNF or anti-IL17A. Methods We systematically reviewed PubMed, EMBase, and Cochrane from inception to May 3, 2020, and searched for placebo-controlled and head-to-head randomized controlled trials (RCTs) assessing anti-TNF monoclonal antibodies (mAb) or soluble receptor fusion protein or anti-IL17A in patients with axSpA according to ASAS criteria and reporting safety data on AU. Data were extracted following a predefined protocol. We did pairwise and network meta-analyses for the primary outcome of AU flares (relapse or de novo) incidence and estimated summary odds ratios (ORs). We assessed the quality of evidence using the Cochrane risk-of-bias 2.0 tool. We ranked treatments according to their effectiveness in preventing AU flare using the P-score. Results We identified 752 citations and included 33 RCTs, comprising 4544 treated patients (anti-TNF mAb 2101, etanercept [ETN] 699, anti-IL17A 1744) and 2497 placebo-receiving patients. Incidence of uveitis was lower with anti-TNF mAb versus placebo (OR = 0.46; CI 95% [0.24; 0.90]) and versus anti-IL17A (OR = 0.34; CI 95% [0.12; 0.92]. According to the P-score, the ranking from the most to the least preventive treatment of uveitis flare was as follows: anti-TNF mAb, ETN, placebo, and anti-IL17A. Conclusion In RCTs assessing anti-TNF and anti-IL17A in axSpA, incident uveitis are rare events. However, this network meta-analysis demonstrates that anti-TNF mAb are associated with a lower incidence of uveitis compared to placebo and anti-IL17A.
Publications scientifiques (2) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Anti-TNF1
▼
Anti-TNF1
▼- Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials
Arthritis research & therapy · 2021 · Journal Article
Roche D, Badard M, Boyer L, Lafforgue P, et al.
📚 22 cit.🎯 RCR 1.68🔬→🩺 Translationnel
Lombalgie1
▼
Lombalgie1
▼- A national media mass campaign improves beliefs and behaviours about low back pain in the general population and in general practitioners
Joint bone spine · 2023 · Journal Article
Bailly F, Badard M, Beaudreuil J, Beauvais C, et al.
📚 5 cit.
Datasets & protocoles partagés
Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials
Collection2021figshareAbstract Background Anterior uveitis (AU) is the most frequent extra-articular feature of axial spondyloarthritis (axSpA). We aimed to assess and compare the incidence of AU in axSpA patients treated with anti-TNF or ant
Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials
Collection2021figshareAbstract Background Anterior uveitis (AU) is the most frequent extra-articular feature of axial spondyloarthritis (axSpA). We aimed to assess and compare the incidence of AU in axSpA patients treated with anti-TNF or ant
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).